Walleye Capital
GLMD icon

Walleye Capital’s Galmed Pharmaceuticals GLMD Stock Holding History

Walleye Capital’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-24,216
Closed -$83.1K – 5487
2024
Q2 		$83.1K Buy
24,216
+20,715
+592% +$90.9K ﹤0.01% 4795
2024
Q1 		$13.8K Sell
3,501
-6,116
-64% -$27.6K ﹤0.01% 5005
2023
Q4 		$52.5K Sell
9,617
-11,197
-54% -$53.3K ﹤0.01% 4283
2023
Q3 		$155K Buy
+20,814
New +$276K ﹤0.01% 3722

Other funds holding GLMD

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $334M AUM 26.48% 1-Year Est. Return

Walleye Capital's GLMD Position: Q3 2024 in Review

Walleye Capital sold out of Galmed Pharmaceuticals (GLMD) in Q3 2024, closing a stake of 24,216 shares — an estimated $83.1K sold.

Walleye Capital first reported a position in GLMD in Q3 2023 and held it in 4 quarters. The position peaked at $155K in Q3 2023. 10 funds tracked by Wall St. Rank hold GLMD as of Q3 2024.

  • Walleye Capital reported no remaining Galmed Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Walleye Capital sold 24,216 Galmed Pharmaceuticals shares in Q3 2024, an estimated $83.1K.
  • Walleye Capital first reported a position in Galmed Pharmaceuticals in Q3 2023 and held it in 4 quarters.
  • Walleye Capital's Galmed Pharmaceuticals position peaked at $155K in Q3 2023.
  • 10 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.